Ildong Pharmaceutical said on the 5th that it held an extraordinary board meeting and appointed Lee Jae-joon, president, as co-CEO. With the move, the company shifts to a co-CEO system led by Chair and CEO Yoon Woong-seop and CEO Lee Jae-joon.
Ildong Pharmaceutical explained that the transition to a co-CEO system is meant to strengthen expertise in research and development (R&D) and global business and to establish a more balanced decision-making structure. The aim is to expand revenue generation through the global commercialization of new drug projects and to reinforce accountable management in the course of pursuing mid- to long-term strategies.
CEO Lee Jae-joon joined Ildong Pharmaceutical in 2022 and, as head of the global business division, has overseen global strategy, overseas sales, and business development (BD) across the global business. Starting in 2024, Lee was promoted to chief operating officer (COO) and has supervised key institutional sectors including global business, sales and marketing, research and development, and production.
Lee also serves concurrently as CEO of Ildong Pharmaceutical's R&D affiliates, including Unovia and iReedBMS, and is leading new drug development. Going forward, Lee plans to focus on the growth of core businesses and improved profitability, while concentrating on the realization of tangible revenue through the commercialization of new drugs, including licensing.